
09/05/2025
Pneumococcal disease is an infection caused by bacteria. It can lead to life threatening symptoms like meningitis, sepsis, and pneumonia. As children under 2 years of age are at increased risk, routine pneumococcal vaccination is strongly recommended. The purpose of this study is to learn more about the vaccine, called PCV21, in infants who are approximately 2 months of age and older. PCV21 has already been tested in several other studies. None of the conducted studies showed any safety concerns.
Ages: 42 - 89 days old
Compensation: Up to $1,182.50
Visits: 6 Visits
Contact Clinical Research Prime for more information at 208.521.1143 or 208.521.1459. Visit us at
clinical research prime Pneumococcal: Infants 42-89 Days Old Phase 2 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31, a 31-Valent pneumococcal conjugate vaccine, to Prevnar 20, when administered concomitantly with routine pediatric vaccinations. May provide routine....